A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study

Clinical trial NCT05899049 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05899049
Sponsor: Merck Sharp & Dohme LLC
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Carcinoma, Renal Cell

Start date: 2022-07-27
Primary completion: 2027-06-07
Enrollment: 249

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.